Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age1+
SponsorChildren's Hospital of Philadelphia
About this trial
The primary objective of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia Institutional Review Board (IRB) approved protocols that utilize CliniMACs technology for T depletion.
Eligibility criteria
Qualifiers
Metabolic storage diseases correctable by HSCT
Bone marrow failure syndromes
Immunodeficiencies/immune dysregulation syndromes
Sickle cell disease or thalassemia
Disqualifiers
Uncontrolled bacterial, viral, or fungal infections
Fully HLA matched sibling donor (fully matched related donors including siblings may be included in special circumstances)
Donor unable to donate peripheral stem cells
Pregnant Females
Trial design
Treatments tested in this trial
- Apha/beta T and CD19+ cell depletion using CliniMACS device
Treatment groups
No treatment groups listed
Locations
1Children's Hospital of Philadelphia19104, PhiladelphiaPennsylvania, United States
Sponsors and collaborators
Children's Hospital of Philadelphia
Lead sponsor
Source ClinicalTrials.gov